Date: May 30-31, 2019
Venue: Polsky Center for Entrepreneurship and Innovation
Date: May 30-31, 2019
Venue: Polsky Center for Entrepreneurship and Innovation
May 31 – June 1, 2018
Renaissance Schaumburg Convention Center Hotel
Terry Opgenorth, Ph.D; Ex-Vice President, Abbott Laboratories, Vice President, CSU Ventures
Mary Nell and Ralph B. Rogers Professor of Immunology, UT Southwestern Medical Center
Executive Vice President, Athenex
Professor & Vice President for Research, the University of Chicago
Professor, University of Chicago
President, Yao Yuan
Chairman, Tong Xie Yi
October 7, 2017, 2:00 -5:00 PM
Holiday Inn 3405 W Algonquin Rd, Rolling Meadows, IL 60008
October 7, 2017
2:00 – 2:30 PM
“Strategy, Value Proposition, and Investment Guidelines”
Gavin Xia, Ph.D, Principal, Lilly Asia Ventures
Haipeng Cheng, Ph.D, Head, North America, Sangel Venture Capital
Daniel Wang, Member, Hyde Park Angels
Weiqiang Huang, Ph.D, Managing Partner, HeYongWeiMing Venture
2:30 – 5:00 PM
2:30 – 2:50 PM
“Next Generation Therapeutics to Improve Outcomes for Patients with Chronic Kidney Disease and Osteoporosis”
Ruth Wu-Wong, Ph.D., CSO and Founder, Vidasyn Inc.
2:50 – 3:10 PM
“Breakthrough Therapies for Alzheimer’s and Parkinson’s Disease”
Russell Dahl, Ph.D., CEO and Founder, Neurodon LLC
3:10 – 3:30 PM
“HuTARG Technology for Production of Human Antibody”
Kevin Zhang, Ph.D., CSO, Innovative Targeting Solutions, Inc., Canada
3:30 – 3:50 PM
Jim Lu, MD, President, GoPath Laboratories, Inc.
3:50 – 4:10 PM
Michael T. Flavin, Ph.D., CEO, Shamrock Structures LLC
4:10 – 4:30 PM
“Novel Artesunate Formulation and Clinical Applications”
Mitch Zhao, Ph.D., CEO, Glycopep Corp.
4:30 – 4:50 PM
“Core CLIA IVD Reagent CDMO and Value Added Services”
Yingqing Huang, Ph.D., President and Founder, Innokare LLC
To register, send an email to email@example.com
Address & Map
For over two decades, Dr. Yusuke Nakamura has made important contributions to genomic medicine and cancer research. His work has had a significant impact on the progress of genomic medicine worldwide. He is one of the pioneers in variable number tandem repeat (VNTR) and single nucleotide polymorphism (SNP) marker research, and in using genomics research findings to develop clinical interventions. These DNA polymorphic markers have made it possible to map and clone genes responsible for hereditary diseases and various cancers, and to identify those susceptible to common diseases and those related to variable drug response. In recent years, he has been developing anticancer drugs, including antibodies and peptide vaccines, and molecular-targeting small molecular compounds through the discovery of important genes in development and progression of cancers by the genome-wide approach.
Dr. Nakamura has published more than 1,300 articles in such publications as the American Journal of Human Genetics, Cancer Research, Genomics, Nature, Nature Cell Biology, Nature Genetics, Oncogene, and Science. In 2010, Nakamura received the Chen Award for Distinguished Academic Achievement in Human Genetic and Genomic Research, an honor bestowed by the Human Genome Organisation (HUGO).
Dr. Nakamura graduated from Osaka University Medical School and earned a PhD in molecular genetics from the same institution. He joined the University of Chicago faculty in 2012.
1984 Research Associate, Howard Hughes Medical Institute, University of Utah
1987 Research Assistant Professor, Department of Human Genetics, University of Utah
1989 Head, Biochemistry Department, Cancer Institute, Tokyo, Japan
1994 Professor, Institute for Medical Science, University of Tokyo
1995 Director, Human Genome Center, University of Tokyo
2005 Director, RIKEN Center for Genomic Medicine
2011 Special Advisor to the Cabinet, Secretary General, Office of Medical Innovation, Cabinet Secretariat, Government of Japan
2012 Professor of Medicine, Section of Hematology/Oncology, Deputy Director, Center for Personalized Therapeutics, University of Chicago
新浪医药 Nature《自然》 GBI 兴证医药健康
火石创造 苏比亚 易贸医疗 米内网 投壶网
药渡经纬 健点子ihealth HPC药闻药事
研发客 汤森路透 医药信息新药开发群
医药研发社交平台 医药地理 医药魔方药智网
宁静访谈录 汇聚南药 药物临床试验网
咸达数据 海川会 当代医生 中睿医药评论
中国医药报 医药经济报 Insight 数据库
新药汇 药物一致性评价 药研 洛施德GMP咨询
赵英明博士：芝加哥大学教授，中科院上海药物所特聘教授，美国人类蛋白质组学组织（US HUPO）理事，中国CN HUPO副理事长。实验室首次报道了八种新蛋白质修饰类型，首次鉴定了近350种新型表观遗传学组蛋白修饰密码。在Cell、Nature、Science等期刊发表论文140余篇。被引用超过16,700次，H-index 66。其中赖氨酸巴豆酰修饰通路相关成果在2011年被评为Cell杂志年度五项突破性成果之一。
黄振华，同写意新药英才俱乐部理事，山东亨利医药科技有限责任公司总裁兼首席执行官，先后创办了山东轩竹医药科、 KBP BIOSCIENCES PTE. LTD.（新加坡）、山东亨利医药科技和KBP BIOSCIENCES USA. INC（美国）。山东轩竹曾申报7个1.1类新药。山东亨利3个1.1类新药已获FDA临床许可，完成一个II期临床和2个I期临床试验。作为主要发明人已有200多件专利授权。提出Me-only的新药研发理念和新药研发三定律。
Peter Senter博士：西雅图遗传制药公司副总裁，华盛顿大学教授，美国化学会《Bioconjugate Chemistry》杂志前主编，1998年以来一直在纳斯达克上市公司西雅图遗传公司（Seattle Genetics, Inc.）工作，2002年起任主管化学的副总裁。之前曾就职Cytokine Networks公司、BMS以及哈佛大学医学院Dana-Farber癌症研究中心。Senter博士是世界ADC领域的先驱。美国化学会《Bioconjugate Chemistry》上一任主编，获得50余项专利授权。
12:30 午餐 会议结束
Welcome to the 10th Yao Yuan Biotech-Pharma Symposium. This is the tenth in a series of annual Yao Yuan conferences, and will be the first that we have the honor of co-sponsoring the meeting with the University of Chicago.
Advances in medicine are often driven by significant improvements in technology. New technologies may open broad new avenues of research and give rise to novel and highly effective treatment approaches. For example, recent years have witnessed significant advances towards realizing the promise of “personalized medicine”, driven largely by improved “omics” technologies, advances in chemical biology, and an improving ability to design the right drugs for the right patients. New technologies may also enable scientists to revisit old (but good) concepts whose promise has gone unrealized. The recent explosion of the immuno-oncology (I-O) field represents an excellent example, as scientists and clinicians are learning how to harness the power of the human immune system for the eradication of cancer cells. In this forum, our speakers will present striking examples of breakthroughs in chemistry, biology, immunology and genomics that are driving the future of drug discovery and, ultimately, the development of better medicines.
Continuing with last year’s emphasis on student attendees, there will be a poster competition sponsored by ACS Medicinal Chemistry Letters and the Journal of Medicinal Chemistry. In addition, there will be a discussion panel focusing on entrepreneurship in science, featuring outstanding industrial, academic and venture capital panelists who will discuss a variety of hot topics on start-up enterprises. The detailed program can be found on the conference website at www.yypharm.org/symposium/2017.
This event provides a valuable opportunity for learning amongst professionals, academicians and students, and serves as a platform for discussions around many themes central to the world of drug discovery. Though primarily intended to be a Midwest regional gathering, e.g., Illinois, Indiana, Iowa and Wisconsin, this symposium has attracted participants from other regions as well as international attendees. We hope that you enjoy the day. We’re all looking forward to it!
Joel D. Leverson, Ph.D. Wenbin Li, Ph.D
Scientific Director, Oncology Development James Franck Professor of Chemistry
AbbVie, Inc. University of Chicago
Zhong-Yin Zhang graduated from Nankai University, China, with a B.S. in Chemistry in 1984. He obtained a Ph.D. in Chemistry from Purdue University in 1990. After a brief stint at Upjohn, he completed his postdoctoral training at the University of Michigan. Dr. Zhang established his own laboratory in 1994 at Albert Einstein College of Medicine, where he rose to the rank of Professor in 2002. From 2005-2015, Dr. Zhang was Robert A. Harris Professor and Chairman of the Department of Biochemistry and Molecular Biology at Indiana University School of Medicine. In 2016, Dr. Zhang moved back to Purdue as Distinguished Professor of Medicinal Chemistry, Robert C. and Charlotte P. Anderson Chair in Pharmacology, and Head of the Department of Medicinal Chemistry and Molecular Pharmacology. He is also program leader of the medicinal chemistry program in Purdue Center for Cancer Research. He also serves as the Director for the Chemical Genomics Facility in Purdue Institute for Drug Discovery.
Dr. Zhang’s research spans the disciplines of chemistry and biology with an emphasis on the structure and function of protein tyrosine phosphatases (PTPs), and development of PTP inhibitors as novel therapeutics. His group performed experiments that defined the catalytic mechanism, rate-limiting step, and transition state of the PTP-catalyzed reaction; probed the molecular basis for PTP substrate recognition; and elucidated biochemical mechanisms for a number of PTP-mediated cellular signaling pathways. In addition, he has pioneered a novel paradigm for the acquisition of potent and selective PTP inhibitors by targeting both the PTP active site and unique pockets in the vicinity of the active site. His group developed a number of nonhydrolyzable pTyr pharmacophores that are sufficiently polar to bind the PTP active site, yet remain capable of efficiently crossing cell membranes, offering PTP inhibitors with both high potency and excellent in vivo efficacy in animal models of oncology, diabetes/obesity, autoimmunity, and tuberculosis. These efforts have produced numerous first-in-class PTP inhibitors that have become widely used to interrogate PTP function in normal physiology and in disease states and have also inspired drug discovery programs. He has authored more than 245 publications, holds 17 patents, consults for several pharmaceutical companies, and he is an internationally recognized authority in the field of PTPs.
• M.D. University of Montreal
• Residencies in Internal Medicine (University of Montreal and McGill University) and Clinical Immunology and Allergy (McGill University)
• Past positions in the Faculties of Medicine at McGill University and the University of Toronto
• Fellow of the Royal Society of Canada
• Officer of the Order of Canada
Prior to joining AbbVie, Dr. Hudson was the President and Scientific Director of the Ontario Institute for Cancer Research, where he led the institute’s work in translational research for the prevention, detection, diagnosis and treatment of cancer. This led to the development of numerous partnerships with industry and the launch of over 20 companies.
Internationally renowned for his work in genomics and human genome variation, his past positions include leadership roles as Founder and Director of the McGill University and Genome Quebec Innovation Centre and Assistant Director of the Whitehead/MIT Center for Genome Research. Dr. Hudson has been a key player in many national and international organizations. He was a founding member of the International Haplotype Map Consortium, the International Cancer Genome Consortium and the Global Alliance for Genomics and Health. Dr. Hudson’s research has also focused on the genetic dissection of complex diseases. He was involved in many important discoveries of genes involved in the predisposition to colon cancer and chronic diseases including Type II diabetes, leprosy, multiple sclerosis, asthma and inflammatory bowel disease. Dr. Hudson has co-authored more than 300 peer-reviewed scientific publications.
Dr. Hudson has been a scientific advisor to many public organizations, including Genome Canada, Genome England, the National Human Genome Research Institute (NIH) and the STARR Cancer Foundation (USA).
Y. Lynn Wang, MD, PhD, FCAP, is a Professor of Pathology at the University of Chicago Medicine. Dr. Wang served as the Founding Division Director of the Genomic and Molecular Pathology. Under her leadership, her team successfully brought live17 new clinical grade genetic tests in three years, including several nextgen sequencing testing panels for personalized cancer care.
As a physician-scientist and the Director of Lymphoma Translational Pathology, Dr. Wang is the principal investigator of several translational research projects on aberrant signal transduction pathways in B-cell lymphoma and leukemia. The Wang lab is one of the pioneers who explored the idea of targeting BCR signaling in lymphoid malignancies before BCR-directed therapies became widely known and used for patient treatment. Using inhibitors of LYN, SYK and BTK, the lab has demonstrated the critical role of BCR signaling in lymphoma cell proliferation and survival in diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Dr. Wang’s work on B-cell receptor signaling and BCR-targeted therapies has extended to the characterization of the molecular mechanisms underlying drug sensitivity and resistance. In particular, Wang lab contributed significantly to the understanding of the mechanisms leading to resistance to SYK and BTK inhibition. In May 2014, the lab reported their discovery of BTKC481S mutation in a CLL patient with ibrutinib (a BTK inhibitor) resistance in the NEJM which was followed by several studies elucidating the molecular mechanisms of primary and secondary resistance to ibrutinib in CLL and MCL.
Wang Lab has contributed more than 60 original works to quality peer-reviewed scientific and medical journals and she is the major contributor in 35 of them. Dr. Wang has been invited to deliver more than 70 oral presentations at national or international forums. She reviews manuscripts for many professional journals including Blood, Leukemia, Cancer Cell and Science Translational Medicine.
Dr. Wang received her MD from Beijing Medical University in 1988 (conferred to a US MD degree in 2002) and her PhD from Brandeis University in 1996. She completed her Clinical Pathology Residency, Clinical Molecular Pathology Fellowship and postdoctoral research training at the University of Pennsylvania. She is board-certified in Clinical Pathology and Molecular Genetic Pathology. Before joining the faculty of the University of Chicago, she directed the Molecular Hematopathology Laboratory and her lymphoma translational research laboratory at Weill Cornell Medical College for eleven years.